GSK and Lonza Sign Manufacturing Deal

Lonza says it has entered into an agreement with GlaxoSmithKline (GSK; London) under which Lonza will support the ongoing development of GSK’s biopharmaceutical pipeline by supplying manufacturing capacity for five early stage monoclonal antibodies. Lonza will initially manufacture clinical trial batches of five compounds currently in Phase 1 and 2 for GSK, under the terms of the deal. Lonza will also provide access to flexible capacity to enable GSK to respond to future demand dependent upon progression of molecules through late stage development and...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers